Clinical trials: Ticagrelor
Ischemia
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by forearm blood flow (FBF) measurement before and 10 min after a 20 min…
- Trial name
- NCT02910778
- Testing
- Atorvastatin, Ticagrelor
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Intracranial Aneurysm, Stent Complication
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm
The primary goal of the trial is to investigate whether the experimental arms (receiving the P2Y12 inhibitor Ticagrelor) compared with the control arm (taking dual antiplatelet therapy) could reduce bleeding complications in…
- Trial name
- SAC-TIDE (NCT06015477)
- Testing
- Ticagrelor monotherapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Chronic Kidney Disease (CKD)
Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD).
- Trial name
- TACTIC-CKD (NCT07911124)
- Testing
- Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Acute Coronary Syndrome
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers
A randomized, open-label, single dose, crossover study to evaluate pharmacokinetic profiles and safety/tolerability of CKD-357 in healthy volunteers
- Trial name
- NCT03671941
- Testing
- D578, CKD-357
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
This is a Phase 2A, randomized, double-blind, placebo-controlled, single dose, sequential group study to evaluate the safety, tolerability, PK, and PD of PB2452 vs matching placebo with ticagrelor (with or without acetylsalicylic…
- Trial name
- NCT03928353
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Optical Coherence Tomography, Dual Antiplatelet Therapy
OCT or Angiography Guided De-escalation of DAPT
Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus.
- Conditions
- Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage
- Trial name
- NCT06339021
- Testing
- OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shenyang Northern Hospital
Drug Drug Interaction
Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers
Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers
- Trial name
- NCT01350921
- Testing
- Ticagrelor, Venlaflaxin
- Where
- 2 sites in United States, Sweden
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Individuals
Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
Single oral administration of study drugs (i.e. Anplag® \& Brilinta®) in Two periods after at least 10 hours fasting. The periods will be separated by a washout period of 7 days.
- Trial name
- BE (NCT04941196)
- Testing
- Anplag (Ticagrelor 90 mg), Brilinta (Ticagrelor 90 mg)
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Healthy Participants
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
The purpose of this study is to measure the effect of ticagrelor on the pharmacokinetics (PK) of rosuvastatin in healthy participants.
- Trial name
- NCT06554821
- Testing
- Rosuvastatin, Ticagrelor
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
AZD6140 Oral Contraceptive Interaction Study
The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.
- Trial name
- NCT00685906
- Testing
- AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes
Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The aim of the first project is to…
- Trial name
- PANDDA (NCT02302508)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Pharmacokinetics
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine.
- Trial name
- KF2019#1 (NCT05373277)
- Testing
- Ticagrelor, Rosuvastatin
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Healthy
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese
This study is a open and single center clinical trial in healthy Chinese.The objective of the study is to clarify the pharmacokinetics characteristics and antiplatelet effects of ticagrelor in Chinese and to investigate the…
- Trial name
- IGPPT (NCT03092076)
- Testing
- Ticagrelor
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Carotid Stenosis
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting
patients undergoing carotid stenting take dual anti platelet therapy to prevent thrombotic complications usually used drugs are aspirin plus clopidogrel but there are patients not respond so ticagrelor may be an effective and…
- Trial name
- NCT04091074
- Testing
- Ticagrelor, Clopidogrel, Carotid stenting
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Assiut University
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Acute Coronary Syndrome
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
Background: Coronary heart disease is the most common cause of death in industrialized countries. Revascularisation by percutaneous coronary angioplasty or thrombolysis is the main principle for treatment of the acute coronary…
- Trial name
- NCT02120092
- Testing
- Clopidogrel, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Platelet Dysfunction, Von Willebrand Diseases
Clinical Performance Evaluation of T-TAS 01 PL Chip
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Trial name
- NCT03621020
- Testing
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Where
- 6 sites in United States, France
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Hikari Dx, Inc.
Endotoxemia
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
Rationale: In patients suffering a myocardial infarction the P2Y12 receptor antagonists prasugrel and ticagrelor improve outcome and prognosis compared to clopidogrel.
- Trial name
- NCT02612480
- Testing
- ticagrelor, Clopidogrel, Acetylsalicylic acid lysinate
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center